You are here

Article info

Article menu
XML
Immune cell therapies and immune cell engineering
Original research
High-affinity T-cell receptor specific for MyD88 L265P mutation for adoptive T-cell therapy of B-cell malignancies

Authors

  • Özcan Çınar Department of Hematology, Oncology and Tumor Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, GermanyMax-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany PubMed articlesGoogle scholar articles
  • Bernadette Brzezicha Experimental Pharmacology and Oncology Berlin-Buch GmbH (EPO), Berlin, Germany PubMed articlesGoogle scholar articles
  • Corinna Grunert Department of Hematology, Oncology and Tumor Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, GermanyMax-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany PubMed articlesGoogle scholar articles
  • Peter Michael Kloetzel Institute of Biochemistry, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany PubMed articlesGoogle scholar articles
  • Christin Beier Institute of Biochemistry, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany PubMed articlesGoogle scholar articles
  • Caroline Anna Peuker Department of Hematology, Oncology and Tumor Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany PubMed articlesGoogle scholar articles
  • Ulrich Keller Department of Hematology, Oncology and Tumor Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, GermanyMax-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany PubMed articlesGoogle scholar articles
  • Antonio Pezzutto Department of Hematology, Oncology and Tumor Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, GermanyMax-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany PubMed articlesGoogle scholar articles
  • Antonia Busse Department of Hematology, Oncology and Tumor Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, GermanyMax-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany PubMed articlesGoogle scholar articles

Citation

Çınar Ö, Brzezicha B, Grunert C, et al
High-affinity T-cell receptor specific for MyD88 L265P mutation for adoptive T-cell therapy of B-cell malignancies
Journal for ImmunoTherapy of Cancer 2021;9:e002410. doi: 10.1136/jitc-2021-002410
Online issue publication 
November 02, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.